Shopping Cart
- Remove All
Your shopping cart is currently empty
Rimegepant, also known as BMS-927711 and BHV-3000, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraines. Rimegepant has shown in vivo efficacy without vasoconstriction effect. BMS-927711 is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $2,870 | 10-14 weeks | |
| 50 mg | $3,780 | 10-14 weeks | |
| 100 mg | $5,200 | 10-14 weeks |
| Description | Rimegepant, also known as BMS-927711 and BHV-3000, is a potent, selective, competitive, and orally active calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraines. Rimegepant has shown in vivo efficacy without vasoconstriction effect. BMS-927711 is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile. |
| Molecular Weight | 1221.2526 |
| Formula | C56H64F4N12O13S |
| Cas No. | 1374024-48-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.